Summary & Overview
CPT 81334: RUNX1 Targeted Sequence Analysis, Technical Component
CPT code 81334 identifies the technical component of a molecular test that detects targeted sequence changes in the RUNX1 gene (for example, exons 3–8). This genetic assay is used in diagnostic workflows where detection of RUNX1 variants informs hematologic disease evaluation and management. The code matters nationally as precision-medicine genetic testing expands across clinical laboratories and hospital systems, affecting utilization, billing workflows, and payer coverage policies.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical context of RUNX1 targeted sequencing, typical sites of service, and the role of the technical laboratory component in reporting and billing. The publication also outlines common modifiers and operational considerations relevant to labs and billing teams.
This summary prepares readers for detailed sections covering reimbursement benchmarks, payer policy variations, coding guidance, and clinical implications of RUNX1 targeted testing. Data not available in the input will be noted where applicable.
Billing Code Overview
CPT code 81334 describes the technical laboratory test performed to detect specific changes in the runt related transcription factor 1 (RUNX1) gene using targeted sequence analysis (for example, testing exons 3–8). This service involves laboratory processing, sequencing, and interpretation steps required to identify sequence variants in the specified regions of the RUNX1 gene.
Service type: Molecular genetic targeted sequence analysis (technical component)
Typical site of service: Clinical molecular genetics laboratory or hospital laboratory
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with a history of ambiguous myeloid neoplasm presents with persistent cytopenias and bone marrow dysplasia. The treating hematologist orders targeted RUNX1 gene sequencing to identify pathogenic variants in exons 3–8 to clarify diagnosis, inform prognosis, and guide therapy selection. A peripheral blood or bone marrow specimen is collected and sent to a molecular diagnostics laboratory. The lab analyst performs the technical sequencing and bioinformatic processing to detect specific RUNX1 alterations. The result is reviewed by a board-certified molecular pathologist who issues the interpretive report. Typical sites of service include hospital-based molecular laboratories, independent clinical reference laboratories, and academic medical center molecular pathology labs. Typical workflow steps: specimen collection (blood or bone marrow) → specimen accessioning and DNA extraction → targeted sequence analysis of RUNX1 (exons 3–8) → data analysis and variant calling → quality control and interpretation → result reporting to the ordering hematologist.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the professional interpretation by the pathologist separate from the technical lab work |
TC |